Caligan Partners’s RAPT Therapeutics RAPT Stock Holding History

Caligan Partners’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-644,400	Closed	-$21.8M	–	33
2025 Q4	$21.8M	Buy	+644,400	New	+$20M	1.8%	15

Caligan Partners's RAPT Position: Q1 2026 in Review

Caligan Partners sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 644,400 shares — an estimated $21.8M sold.

Caligan Partners first reported a position in RAPT in Q4 2025 and held it in 1 quarter. The position peaked at $21.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Caligan Partners reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Caligan Partners sold 644,400 RAPT Therapeutics shares in Q1 2026, an estimated $21.8M.
Caligan Partners first reported a position in RAPT Therapeutics in Q4 2025 and held it in 1 quarter.
Caligan Partners's RAPT Therapeutics position peaked at $21.8M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Caligan Partners's 13F filing for Q1 2026, filed 15 May 2026.